Latanoprost contraindications

The ocular hypotensive lipids in typical ophthalmology practice are considered first-line alternatives to topical P-blockers because of their superior efficacy and safety profiles. Many clinicians may choose to use the ocular hypotensive lipids as first-line agents, especially in patients that have an initial requirement to lower IOP by more than 25%, or in patients that have relative or absolute contraindications to topical P-blockers. However, latanoprost is currently the only ocular hypotensive lipid drug that has a Food and Drug Administration (FDA) indication for first-line therapy. Bimatoprost and travoprost are indicated by the FDA for patients who are intolerant of other IOP-lowering therapy or insufficiently responsive to another IOP-lowering medication.10,38... 

With regard to topical NSAIDs, there are few significant contraindications. One reported interaction is between oral indomethacin and topical brimonidine. Patients taking this oral medication were found to have escape of lOP control when using brimonidine. However, the study foiled to demonstrate such loss of lOP-lowering control with latanoprost. 

---